Breaking News

Banco Espirito Santo Drops as Much as 41.5% in Lisbon Trading
Tweet TWEET

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

  LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue
  Contingent Interest

Business Wire

BURLINGTON, N.C. -- September 12, 2013

Laboratory Corporation of America^® Holdings (LabCorp^®) (NYSE: LH) announced
today that for the period of September 12, 2013 to March 11, 2014, its Zero
Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will,
subject to the terms of the Zero Coupon Notes, accrue contingent cash interest
at a rate of no less than 0.125% of the average market price of a Zero Coupon
Note for the five trading days ended September 9, 2013, in addition to the
continued accrual of the original issue discount. Contingent cash interest,
which the Company has determined to be approximately $1.62 per Note, will be
payable to holders of the Zero Coupon Notes as of the record date, which is
February 24, 2014. The payment of contingent cash interest is expected to be
made on March 11, 2014.

About LabCorp^®

Laboratory Corporation of America^® Holdings, an S&P 500 company, is a pioneer
in commercializing new diagnostic technologies and the first in its industry
to embrace genomic testing. With annual revenues of $5.7 billion in 2012, over
34,000 employees worldwide, and more than 220,000 clients, LabCorp offers more
than 4,000 tests ranging from routine blood analyses to reproductive genetics
to companion diagnostics. LabCorp furthers its scientific expertise and
innovative clinical testing technology through its LabCorp Specialty Testing
Group: The Center for Molecular Biology and Pathology, National Genetics
Institute, ViroMed Laboratories, Inc, The Center for Esoteric Testing,
Litholink Corporation, Integrated Genetics, Integrated Oncology, Dianon
Pathology, Monogram Biosciences, Inc, Colorado Coagulation, Cellmark
Forensics, MedTox, and Endocrine Sciences. LabCorp conducts clinical trials
testing through its LabCorp Clinical Trials division. LabCorp clients include
physicians, government agencies, managed care organizations, hospitals,
clinical labs, and pharmaceutical companies. To learn more about our
organization, visit our Web site at: www.labcorp.com.

This press release contains forward-looking statements. Each of the
forward-looking statements is subject to change based on various important
factors, including without limitation, competitive actions in the marketplace
and adverse actions of governmental and other third-party payors. Actual
results could differ materially from those suggested by these forward-looking
statements. Further information on potential factors that could affect
LabCorp’s financial results is included in the Company’s Form 10-K for the
year ended December 31, 2012, and subsequent SEC filings.

Contact:

Laboratory Corporation of America^® Holdings
Stephen Anderson, 336-436-5076
www.labcorp.com